半剂量维替泊芬光动力疗法治疗复发性中心性浆液性脉络膜视网膜病变的临床观察
|
摘要
目的探讨半剂量维替泊芬光动力疗法治疗复发性中心性浆液性脉络膜视网膜病变的临床效果。方法选取2016年6月至2017年5月于内蒙古自治区赤峰市第二医院眼科确诊为复发性中心性浆液性脉络膜视网膜病变的患者8例(10只眼)。全部患者均采用维替泊芬光动力进行治疗,按照1999年北美和欧洲发表的多中心光动力疗法治疗老年性黄斑变性的药剂使用标准确定患者药剂用量。给予患者常规光动力治疗标准剂量的一半,即根据患者体表面积,静脉注射维替泊芬3 mg/m2,注药结束15 min后,采用光照能量为50 J/cm2、功率密度为600 m W/cm2及体激光波长为689 nm的激光裂隙灯照射83 s。采用单因素重复测量方差分析的方法比较患者治疗前后各时间点的最佳矫正视力(BCVA)及黄斑部视网膜厚度(CMT)的变化。结果治疗前,患者的BCVA为0.2~0.5,平均为0.34±0.12,治疗3个月后,经复查,患者的BCVA为0.4~1.2,平均为0.78±0.24,患者视力显著提高,差异有统计学意义(t=-5.18,P<0.05)。治疗3个月后,全部患者均接受光学相干断层扫描检查。检查结果显示,8例(10只眼)患者中,9只患眼完全治愈,即中心凹处视网膜下液完全吸收,占全部患者的90%。1只患眼未完全治愈,占全部患者的10%,患者再次接受治疗后痊愈。治疗后6个月时再次进行复查,经光学相干断层扫描检查,8例(10只眼)患者完全治愈。患者治疗前的CMT为(349±91)μm,治疗后1个月时为(192±60)μm,治疗后3个月时为(184±64)μm,治疗后6个月时为(177±56)μm。经单因素重复测量方差分析,患者各时间点的CMT差异有统计学意义(F=78.22,P<0.05)。与治疗前相比,治疗后1个月、3个月及6个月的结果均显著优于治疗前,差异有统计学意义(t=4.32,4.45,4.83;P<0.05)。且治疗后患者的CMT呈现出持续下降的趋势。全部患者于术后1个月、3个月及6个月接受随访。至最后一次随访,中心凹处视网膜下液及CMT均未发现复发情况,也未出现任何并发症。结论采用光学相干断层扫描技术,使用半剂量维替泊芬光动力治疗复发性中心性浆液性脉络视网膜病变,可以有效改善患者的脉络膜微循环,缩短患者的病程时间,治疗效果显著。
Objective To investigate the clinical effect of photodynamic therapy with half dose of vepofin in the treatment of recurrent central serous choroidal retinopathy. Methods From June 2016 to May2017,8 patients( 10 eyes) were diagnosed as recurrent central serous choroidal retinopathy in the second ophthalmology hospital of Chifeng,Inner Mongolia. All patients were treated with ventpophen photodynamic.According to the drug use standard of polycentric photodynamic therapy published in North America and Europe in 1999 for the treatment of age-related macular degeneration,the patient was determined. The patients were given half of the standard dose of routine photodynamic therapy,namely,according to the surface area of the patient,intravenous injection of venipofinn3 mg/m2,after the injection of 15 min,the light energy was 50 J/cm2,the power density was 600 m W/cm2,the laser wavelength of body laser was689 nm,and the laser slit lamp irradiated 83 s. The changes of the best corrected visual acuity( BCVA) and retinal thickness( CMT) of the macular region were compared with the method of single factor repeated measurement of variance analysis. Results Before treatment,the BCVA of the patient was 0. 2 ~ 0. 5,the average was 0. 34 ± 0. 12. After 3 months of treatment,the patient's BCVA was 0. 4 ~ 1. 2,the average was0. 78 ± 0. 24. The visual acuity of the patients was significantly improved. The difference was statistically significant( t =-5. 18,P < 0. 05). After3 months of treatment,all patients underwent optical coherence tomography. The results showed that 9 eyes of 8 patients( 10 eyes) were completely cured,that is,the subretinal fluid of the fovea was completely absorbed,accounting for 90% of all patients. 1 eye was not completely cured,accounting for 10% of all patients. At 6 months after treatment,8 patients( 10 eyes)were completely cured after re examination by optical coherence tomography. The CMT before treatment was( 349 ± 91) μm,1 month after treatment( 192 ± 60) μm,3 months after treatment( 184 ± 64) μm,and6 months after the treatment was( 177 ± 56) μm. Single factor repeated analysis of variance showed that there was a significant difference in CMT between patients at different time points( F = 78. 22,P < 0. 05).Compared with before treatment,the results of 1 month,3 months and 6 months after treatment were significantly better than those before treatment,and the difference was statistically significant( t = 4. 32,4. 45,4. 83; P < 0. 05). After treatment,the CMT of patients showed a continuous decline. All patients were followed up for 1 month,3 months and 6 months. At the last follow-up,no recurrence was found in the subretinal fluid and CMT of the fovea and no complications occurred. Conclusion The treatment of recurrent central serous choroidal retinopathy by using optical coherence tomography technique and half dose of veentfin photodynamic therapy can effectively improve the choroidal microcirculation and shorten the duration of the patient's course of disease,and the therapeutic effect is remarkable.
Objective To investigate the clinical effect of photodynamic therapy with half dose of vepofin in the treatment of recurrent central serous choroidal retinopathy. Methods From June 2016 to May2017,8 patients( 10 eyes) were diagnosed as recurrent central serous choroidal retinopathy in the second ophthalmology hospital of Chifeng,Inner Mongolia. All patients were treated with ventpophen photodynamic.According to the drug use standard of polycentric photodynamic therapy published in North America and Europe in 1999 for the treatment of age-related macular degeneration,the patient was determined. The patients were given half of the standard dose of routine photodynamic therapy,namely,according to the surface area of the patient,intravenous injection of venipofinn3 mg/m2,after the injection of 15 min,the light energy was 50 J/cm2,the power density was 600 m W/cm2,the laser wavelength of body laser was689 nm,and the laser slit lamp irradiated 83 s. The changes of the best corrected visual acuity( BCVA) and retinal thickness( CMT) of the macular region were compared with the method of single factor repeated measurement of variance analysis. Results Before treatment,the BCVA of the patient was 0. 2 ~ 0. 5,the average was 0. 34 ± 0. 12. After 3 months of treatment,the patient's BCVA was 0. 4 ~ 1. 2,the average was0. 78 ± 0. 24. The visual acuity of the patients was significantly improved. The difference was statistically significant( t =-5. 18,P < 0. 05). After3 months of treatment,all patients underwent optical coherence tomography. The results showed that 9 eyes of 8 patients( 10 eyes) were completely cured,that is,the subretinal fluid of the fovea was completely absorbed,accounting for 90% of all patients. 1 eye was not completely cured,accounting for 10% of all patients. At 6 months after treatment,8 patients( 10 eyes)were completely cured after re examination by optical coherence tomography. The CMT before treatment was( 349 ± 91) μm,1 month after treatment( 192 ± 60) μm,3 months after treatment( 184 ± 64) μm,and6 months after the treatment was( 177 ± 56) μm. Single factor repeated analysis of variance showed that there was a significant difference in CMT between patients at different time points( F = 78. 22,P < 0. 05).Compared with before treatment,the results of 1 month,3 months and 6 months after treatment were significantly better than those before treatment,and the difference was statistically significant( t = 4. 32,4. 45,4. 83; P < 0. 05). After treatment,the CMT of patients showed a continuous decline. All patients were followed up for 1 month,3 months and 6 months. At the last follow-up,no recurrence was found in the subretinal fluid and CMT of the fovea and no complications occurred. Conclusion The treatment of recurrent central serous choroidal retinopathy by using optical coherence tomography technique and half dose of veentfin photodynamic therapy can effectively improve the choroidal microcirculation and shorten the duration of the patient's course of disease,and the therapeutic effect is remarkable.
引文
[1]黎蕾,袁非,徐格致,等.光动力疗法治疗慢性或复发性中心性浆液性脉络膜视网膜病变[J].中华眼科杂志,2012,48(2):106-113.
[2]张桐梅,韩梅,谢世勇.慢性中心性浆液性脉络膜视网膜病变患者光动力疗法治疗后黄斑区内层和外层视网膜厚度变化观察[J].中华眼底病杂志,2015,31(3):235-239.
[3]Ficker L,Vafidis G,While A,et al.Long-term follow-up of a prospective trial of argon laser photocoagulation in the treatment of central serous retinopathy[J].Br J Ophthalmol,1988,72(11):829-834.
[4]宋丹,赵明威,金恩忠,等.不同剂量维替泊芬光动力疗法与抗血管内皮生长因子药物治疗慢性中心性浆液性脉络膜视网膜病变疗效对比观察[J].华眼底病杂志,2015,31(3):221-225.
[5]李霞波,臧亚楠,王玮,等.中心性浆液性脉络膜视网膜病变与OSAS关系分析[J].潍坊医学院学报,2017,39(5):339-341.
[6]Von Graefe.Ueber centrale recidivierende retinitis[J].Graefes Arch Clin Exp Ophthalmol,1866,12(2):211-215.
[7]陈晓凯.慢性中心性浆液性脉络膜视网膜病变患者双眼脉络膜厚度频域光相干断层扫描检查价值评价[J].中国卫生工程学,2017,16(2):213-214.
[8]朱华英,刘新泉,项敏泓,等.化痰清肝法治疗痰热内蕴型慢性中心性浆液性脉络膜视网膜病变的临床观察[J].河北中医,2017,39(10):1493-1496.
[9]Gass JD.Pathogenesis of disciform detachment of the neuroepithelium[J].Am J Ophthalmol,1967,63(3):1-139.
[10]Kabbinavar F,Hurwitz HI,Fehrenbacher L,et al.PhaseⅡ,Randomized Trial Comparing Bevacizumab Plus Fluorouracil(FU)/Leucovorin(LV)With FU/LV Alone in Patients With Metastatic Colorectal Cancer[J].Journal of Clinical Oncology,2003,21(1):60-65.
[11]Lalwani GA,Rosenfeld PJ,Fung AE,et al.A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration:year 2 of the Pr ONTO Study[J].Am J Ophthalmol,2009,148(1):43-58.
[12]Fung AE,Lalwani GA,Rosenfeld PJ,et al.An optical coherence tomography-guided,variable dosing regimen with intravitreal ranibizumab(Lucentis)for neovascular age-related macular degeneration[J].Am J Ophthalmol,2007,143(4):566-583.
[13]Schmidt EU,Miller JM,Laqua H,et al.Photodynamic therapy with verteporfin for choroidal neovascularization caused by agerelated macular degeneration:results of retreatments in a phase 1and 2 study(comment)(see comments)[J].Archives of Ophthalmology,1999,117(9):1177-1187.
[14]Listed N.Krypton laser photocoagulation for neovascular lesions of ocular histoplasmosis.Results of a randomized clinical trial.Macular Photocoagulation Study Group[J].Archives of Ophthalmology,1987,105(11):1499-1507.
[15]Bressler NM.Photodynamic Therapy of Subfoveal Choroidal Neovascularization in Age-related Macular Degeneration With Verteporfin:One-Year Results of 2 Randomized Clinical TrialsTAP Report 1[J].Arch Ophthalmol,1999,117(10):1329-1345.
[16]Yonemoto LT,Slater JD,Blacharski P,et al.Dose Response in the Treatment of Subfoveal Choroidal Neovascularization in AgeRelated Macular Degeneration:Results of a PhaseⅠ/ⅡDoseEscalation Study Using Proton Radiotherapy[J].Journal of Radiosurgery,2000,3(1):47-54.
[17]Milewski SA,Stoj MJ,Neuwirth J,et al.Indocyanine green angiography-guided laser photocoagulation for occult choroidal neovascularization in age-related macular degeneration[J].Annals of Ophthalmology,2001,33(3):225-230.
[18]Brancato R,Introini U,Bolognesi G,et al.ICGA-guided laser photocoagulation of occult choroidal neovascularization in agerelated macular degeneration.Indocyanine green angiography[J].Retina,2000,20(2):134-142.
[19]Pozzo SD,Parodi MB,Ravalico G.A pilot study of ICG-guided laser photocoagulation for occult choroidal neovascularization presenting as a focal spot in age-related macular degeneration[J].International Ophthalmology,2001,24(4):187-194.
[20]Slakter JS,Yannuzzi LA,Sorenson JA,et al.A Pilot Study of Indocyanine Green Videoangiography-Guided Laser Photocoagulation of Occult Choroidal Neovascularization in AgeRelated Macular Degeneration[J].Arch Ophthalmol,1994,112(4):465-472.
[21]Sorenson JA,Yannuzzi LA,Slakter JS,et al.A pilot study of digital indocyanine green videoangiography for recurrent occult choroidal neovascularization in age-related macular degeneration[J].Archives of Ophthalmology,1994,112(4):473-479.
[22]Mori R,Yuzawa M.Utility of Indocyanine Green AngiographyGuided Laser Photocoagulation of Choroidal Neovascularization in Age-related Macular Degeneration[J].Nippon Ganka Gakkai Zasshi,2002,106(10):621-629.
[23]Lim JI,Aaberg TM,Jr CA,et al.Indocyanine green angiography-guided photocoagulation of choroidal neovascularization associated with retinal pigment epithelial detachment[J].Am J Ophthalmol,1997,123(4):524-532.
[24]姚亮,吕莎莎,刘子瑶,等.康柏西普治疗慢性中心性浆液性脉络膜视网膜病变的疗效[J].国际眼科杂志,2017,17(6):1139-1142.
[25]王文玲,关艳玲,户秀慧.中心性浆液性脉络膜视网膜病变患者脉络膜毛细血管扩张和中心凹下脉络膜厚度关系的研究[J].眼科新进展,2017,37(5):466-468.
[26]臧亚楠,李霞波,王玮,等.中心性浆液性脉络膜视网膜病变脉络膜厚度临床分析[J].潍坊医学院学报,2017,39(4):319-320.
[27]Chen SN,Hwang JF,Tseng LF,et al.Subthreshold Diode Micropulse Photocoagulation for the Treatment of Chronic Central Serous Chorioretinopathy with Juxtafoveal Leakage[J].Ophthalmology,2008,115(12):2229-2234.
[28]张莉,范永,邵瑛.伏格特-小柳原田病与中心性浆液性脉络膜视网膜病变的鉴别诊断分析[J].山西医药杂志,2017,46(12):1446-1448.
[29]梁燕华,宋艳萍,丁琴,等.不同病程中心性浆液性脉络膜视网膜病变光动力疗法治疗前后光相干断层扫描图像特征与视力预后的关系[J].中华眼底病杂志,2015,31(5):425-429.
[30]Zhou R,Xiaolin GU,Xun JH,et al.Classification of Bruch's membrane in the choriocapillario-Bruch's membrane-retinal pigment epithelium complex in central serous chorioretinopathy by optical coherence tomography[J].Chinese Journal of Ocular Fundus Diseases,2011,27(4):323-326.
[31]Zhang P,Wang HY,Zhang ZF,et al.Fundus autofluorescence in central serous chorioretinopathy:association with spectraldomain optical coherence tomography and fluorescein angiography[J].International Journal of Ophthalmology,2015,8(5):1003-1007.
[32]Chan WM,Lam DSC,Lai TYY,et al.Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin:a novel treatment at the primary disease level[J].Br J Ophthalmol,2003,87(12):1453-1458.
[33]Breukink MB,Downes SM,Querques G,et al.Comparing halfdose photodynamic therapy with high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy(the PLACE trial):study protocol for a randomized controlled trial[J].Trials,2015,16(1):419.
[34]Kretz FT,Beger I,Koch F,et al.Randomized Clinical Trial to Compare Micropulse Photocoagulation Versus Half-dose Verteporfin Photodynamic Therapy in the Treatment of Central Serous Chorioretinopathy[J].Ophthalmic Surgery Lasers&Imaging Retina,2015,46(8):837-843.
[35]Lai TYY,Chan WM,Li H,et al.Safety enhanced photodynamic therapy with half dose verteporfin for chronic central serous chorioretinopathy:A short term pilot study[J].Digest of the World Core Medical Journals,2006,90(7):869-874.
[36]Lee PY,Kim KS,Lee WK.Severe choroidal ischemia following photodynamic therapy for pigment epithelial detachment and chronic central serous chorioretinopathy[J].Japanese Journal of Ophthalmology,2009,53(1):52-56.
[37]刘洋,黎蕾,徐格致,等.半剂量光动力疗法治疗慢性中心性浆液性脉络膜视网膜病变二年的疗效评估[J].中华眼科杂志,2016,52(5):328-334.
[38]陆慧琴,王尔茜,陈有信.半剂量维替泊芬光动力疗法治疗慢性中心性浆液性脉络膜视网膜病变疗效观察[J].中华眼底病杂志,2015,31(3):226-229.
[39]廖燕红,陈安颍,刘小天.半剂量维替泊芬光动力疗法治疗纤维蛋白渗出慢性中心性浆液性脉络膜视网膜病变观察[J].中国实用眼科杂志,2017,35(2):163-166.
[40]董道权,董应丽,王志立,等.60%剂量维替泊芬光动力疗法治疗慢性中心性浆液性脉络膜视网膜病变的远期效果及安全性[J].中华实验眼科杂志,2015,33(10):945-948.
[41]陈青山,孙良南,李志,等.PDT联合玻璃体腔注射Bevacizumab治疗慢性中心性浆液性视网膜脉络膜病变观察[J].中国实用眼科杂志,2015,33(8):894-898.
[42]吴艺君,许根贵,莫荔,等.半剂量PDT治疗45岁以上中心性浆液性脉络膜视网膜病变疗效观察[J].国际眼科杂志,2017,17(11):2101-2104.
[43]李鹏程,盛双燕,彭冲,等.半剂量光动力疗法治疗慢性中心性浆液性脉络膜视网膜病变[J].中华眼底病杂志,2011,27(4):327-330.
[44]王玉风.半量维替泊芬光动力疗法对黄斑区脉络膜视网膜病变(中心性浆液性)治疗效果分析[J].北方药学,2017,14(6):43.
[45]Zavoloka O,Bezditko P,Lahorzhevska I,et al.Clinical efficiency of Helicobacter pylori,eradication in the treatment of patients with acute central serous chorioretinopathy[J].Graefes Arch Clin and Exp Ophthalmol,2016,254(9):1737-1742.
[46]Schaal KB,Legarreta AD,Feuer WJ,et al.Comparison between Widefield En Face Swept-Source OCT and Conventional Multimodal Imaging for the Detection of Reticular Pseudodrusen[J].Ophthalmology,2017,124(2):205-214.
[47]Asahi MG,Chon AT,Gallemore E,et al.Photodynamic therapy combined with antivascular endothelial growth factor treatment for recalcitrant chronic central serous chorioretinopathy[J].Clinical Ophthalmology,2017,11(11):2051-2056.
[48]Abouammoh MA.Advances in the treatment of central serous chorioretinopathy.[J].Saudi Journal of Ophthalmology,2015,29(4):278-286.
[49]莫宾,周海英,焦璇,等.中心性浆液性脉络膜视网膜病变的OCTA特点及与ICGA的比较分析[J].国际眼科杂志,2017,17(7):1351-1355.
[50]赵俊华,何剑峰.中心性浆液性脉络膜视网膜病变治疗方法的研究进展[J].中国临床新医学,2017,10(8):816-820.
[51]连海燕,宋艳萍.阈下微脉冲激光光凝对慢性中心性浆液性脉络膜视网膜病变的疗效分析[J].眼科,2017,26(3):185-190.
[52]韦远鹏,杨万初.激光光凝眼底联合卵磷脂络合碘片在中心性浆液性脉络膜视网膜病变治疗中的价值分析[J].临床医药文献电子杂志,2017,4(51):9982-9983.
[53]Golshahi A,Klingmüller D,Holz FG,et al.Ketoconazole in the treatment of central serous chorioretinopathy:a pilot study[J].Acta Ophthalmologica,2010,88(5):576-581.
[54]Artunay O,Yuzbasioglu E,Rasier R,et al.Intravitreal bevacizumab in treatment of idiopathic persistent central serous chorioretinopathy:a prospective,controlled clinical study[J].Current Eye Research,2010,35(2):91-98.
[55]Lee JY,Rohlman CE,Molony LA,et al.Characterization of RPR1,an essential gene encoding the RNA component of Saccharomyces cerevisiae nuclear RNase P[J].Molecular&Cellular Biology,1991,11(2):721-730.
[56]Alejandra D,Alexandre M,Ali D,et al.Oral MineralocorticoidReceptor Antagonists:Real-Life Experience in Clinical Subtypes of Nonresolving Central Serous Chorioretinopathy With Chronic Epitheliopathy[J].Translational Vision Science&Technology,2016,5(2):1-12.
[57]Pryds A,Larsen M.Choroidal thickness following extrafoveal photodynamic treatment with verteporfin in patients with central serous chorioretinopathy[J].Acta Ophthalmologica,2012,90(8):738-743.
[58]Ueng SW,Yuan LJ,Lin SS,et al.Hyperbaric oxygen treatment prevents nitric oxide-induced apoptosis in articular cartilage injury via enhancement of the expression of heat shock protein 70[J].Journal of Orthopaedic Research Official Publication of the Orthopaedic Research Society,2013,31(3):376-384.
[59]Fujita S,Arai Y,Nakagawa S,et al.Combined microwave irradiation and intraarticular glutamine administration-induced HSP70 expression therapy prevents cartilage degradation in a rat osteoarthritis model[J].Journal of Orthopaedic Research Society,2012,30(3):401-407.
[60]Li JS,Zhang W,Kang ZM,et al.Hyperbaric oxygen preconditioning reduces ischemia-reperfusion injury by inhibition of apoptosis via mitochondrial pathway in rat brain[J].Neuroscience,2009,159(4):1309-1315.
[61]Arai Y,Kubo T,Kobayashi K,et al.Adenovirus vectormediated gene transduction to chondrocytes:in vitro evaluation of therapeutic efficacy of transforming growth factor-beta 1 and heat shock protein 70 gene transduction[J].Journal of Rheumatology,1997,24(9):1787-1795.
[62]Weisz G,Lavy A,Adir Y,et al.Modification of in Vivo,and in Vitro,TNF-α,IL-1,and IL-6 Secretion by Circulating Monocytes During Hyperbaric Oxygen Treatment in Patients with Perianal Crohn's Disease[J].Journal of Clinical Immunology,1997,17(2):154-159.
[63]王亚明,付婧.高压氧治疗复发性中浆病23例分析[J].中华医学写作杂志,2003,10(8):723-724.
[64]杨欢.中心性浆液性脉络膜视网膜病变患者的多焦视网膜电图改变以及与视力和黄斑区视网膜下液厚度的相关性[D].南充:川北医学院,2017.
[65]Schl9tzer-Schrehardt U,Viestenz A,Naumann GO,et al.Doserelated structural effects of photodynamic therapy on choroidal and retinal structures of human eyes[J].Graefe's Archive for Clinical&Experimental Ophthalmology,2002,240(9):748-757.
[2]张桐梅,韩梅,谢世勇.慢性中心性浆液性脉络膜视网膜病变患者光动力疗法治疗后黄斑区内层和外层视网膜厚度变化观察[J].中华眼底病杂志,2015,31(3):235-239.
[3]Ficker L,Vafidis G,While A,et al.Long-term follow-up of a prospective trial of argon laser photocoagulation in the treatment of central serous retinopathy[J].Br J Ophthalmol,1988,72(11):829-834.
[4]宋丹,赵明威,金恩忠,等.不同剂量维替泊芬光动力疗法与抗血管内皮生长因子药物治疗慢性中心性浆液性脉络膜视网膜病变疗效对比观察[J].华眼底病杂志,2015,31(3):221-225.
[5]李霞波,臧亚楠,王玮,等.中心性浆液性脉络膜视网膜病变与OSAS关系分析[J].潍坊医学院学报,2017,39(5):339-341.
[6]Von Graefe.Ueber centrale recidivierende retinitis[J].Graefes Arch Clin Exp Ophthalmol,1866,12(2):211-215.
[7]陈晓凯.慢性中心性浆液性脉络膜视网膜病变患者双眼脉络膜厚度频域光相干断层扫描检查价值评价[J].中国卫生工程学,2017,16(2):213-214.
[8]朱华英,刘新泉,项敏泓,等.化痰清肝法治疗痰热内蕴型慢性中心性浆液性脉络膜视网膜病变的临床观察[J].河北中医,2017,39(10):1493-1496.
[9]Gass JD.Pathogenesis of disciform detachment of the neuroepithelium[J].Am J Ophthalmol,1967,63(3):1-139.
[10]Kabbinavar F,Hurwitz HI,Fehrenbacher L,et al.PhaseⅡ,Randomized Trial Comparing Bevacizumab Plus Fluorouracil(FU)/Leucovorin(LV)With FU/LV Alone in Patients With Metastatic Colorectal Cancer[J].Journal of Clinical Oncology,2003,21(1):60-65.
[11]Lalwani GA,Rosenfeld PJ,Fung AE,et al.A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration:year 2 of the Pr ONTO Study[J].Am J Ophthalmol,2009,148(1):43-58.
[12]Fung AE,Lalwani GA,Rosenfeld PJ,et al.An optical coherence tomography-guided,variable dosing regimen with intravitreal ranibizumab(Lucentis)for neovascular age-related macular degeneration[J].Am J Ophthalmol,2007,143(4):566-583.
[13]Schmidt EU,Miller JM,Laqua H,et al.Photodynamic therapy with verteporfin for choroidal neovascularization caused by agerelated macular degeneration:results of retreatments in a phase 1and 2 study(comment)(see comments)[J].Archives of Ophthalmology,1999,117(9):1177-1187.
[14]Listed N.Krypton laser photocoagulation for neovascular lesions of ocular histoplasmosis.Results of a randomized clinical trial.Macular Photocoagulation Study Group[J].Archives of Ophthalmology,1987,105(11):1499-1507.
[15]Bressler NM.Photodynamic Therapy of Subfoveal Choroidal Neovascularization in Age-related Macular Degeneration With Verteporfin:One-Year Results of 2 Randomized Clinical TrialsTAP Report 1[J].Arch Ophthalmol,1999,117(10):1329-1345.
[16]Yonemoto LT,Slater JD,Blacharski P,et al.Dose Response in the Treatment of Subfoveal Choroidal Neovascularization in AgeRelated Macular Degeneration:Results of a PhaseⅠ/ⅡDoseEscalation Study Using Proton Radiotherapy[J].Journal of Radiosurgery,2000,3(1):47-54.
[17]Milewski SA,Stoj MJ,Neuwirth J,et al.Indocyanine green angiography-guided laser photocoagulation for occult choroidal neovascularization in age-related macular degeneration[J].Annals of Ophthalmology,2001,33(3):225-230.
[18]Brancato R,Introini U,Bolognesi G,et al.ICGA-guided laser photocoagulation of occult choroidal neovascularization in agerelated macular degeneration.Indocyanine green angiography[J].Retina,2000,20(2):134-142.
[19]Pozzo SD,Parodi MB,Ravalico G.A pilot study of ICG-guided laser photocoagulation for occult choroidal neovascularization presenting as a focal spot in age-related macular degeneration[J].International Ophthalmology,2001,24(4):187-194.
[20]Slakter JS,Yannuzzi LA,Sorenson JA,et al.A Pilot Study of Indocyanine Green Videoangiography-Guided Laser Photocoagulation of Occult Choroidal Neovascularization in AgeRelated Macular Degeneration[J].Arch Ophthalmol,1994,112(4):465-472.
[21]Sorenson JA,Yannuzzi LA,Slakter JS,et al.A pilot study of digital indocyanine green videoangiography for recurrent occult choroidal neovascularization in age-related macular degeneration[J].Archives of Ophthalmology,1994,112(4):473-479.
[22]Mori R,Yuzawa M.Utility of Indocyanine Green AngiographyGuided Laser Photocoagulation of Choroidal Neovascularization in Age-related Macular Degeneration[J].Nippon Ganka Gakkai Zasshi,2002,106(10):621-629.
[23]Lim JI,Aaberg TM,Jr CA,et al.Indocyanine green angiography-guided photocoagulation of choroidal neovascularization associated with retinal pigment epithelial detachment[J].Am J Ophthalmol,1997,123(4):524-532.
[24]姚亮,吕莎莎,刘子瑶,等.康柏西普治疗慢性中心性浆液性脉络膜视网膜病变的疗效[J].国际眼科杂志,2017,17(6):1139-1142.
[25]王文玲,关艳玲,户秀慧.中心性浆液性脉络膜视网膜病变患者脉络膜毛细血管扩张和中心凹下脉络膜厚度关系的研究[J].眼科新进展,2017,37(5):466-468.
[26]臧亚楠,李霞波,王玮,等.中心性浆液性脉络膜视网膜病变脉络膜厚度临床分析[J].潍坊医学院学报,2017,39(4):319-320.
[27]Chen SN,Hwang JF,Tseng LF,et al.Subthreshold Diode Micropulse Photocoagulation for the Treatment of Chronic Central Serous Chorioretinopathy with Juxtafoveal Leakage[J].Ophthalmology,2008,115(12):2229-2234.
[28]张莉,范永,邵瑛.伏格特-小柳原田病与中心性浆液性脉络膜视网膜病变的鉴别诊断分析[J].山西医药杂志,2017,46(12):1446-1448.
[29]梁燕华,宋艳萍,丁琴,等.不同病程中心性浆液性脉络膜视网膜病变光动力疗法治疗前后光相干断层扫描图像特征与视力预后的关系[J].中华眼底病杂志,2015,31(5):425-429.
[30]Zhou R,Xiaolin GU,Xun JH,et al.Classification of Bruch's membrane in the choriocapillario-Bruch's membrane-retinal pigment epithelium complex in central serous chorioretinopathy by optical coherence tomography[J].Chinese Journal of Ocular Fundus Diseases,2011,27(4):323-326.
[31]Zhang P,Wang HY,Zhang ZF,et al.Fundus autofluorescence in central serous chorioretinopathy:association with spectraldomain optical coherence tomography and fluorescein angiography[J].International Journal of Ophthalmology,2015,8(5):1003-1007.
[32]Chan WM,Lam DSC,Lai TYY,et al.Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin:a novel treatment at the primary disease level[J].Br J Ophthalmol,2003,87(12):1453-1458.
[33]Breukink MB,Downes SM,Querques G,et al.Comparing halfdose photodynamic therapy with high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy(the PLACE trial):study protocol for a randomized controlled trial[J].Trials,2015,16(1):419.
[34]Kretz FT,Beger I,Koch F,et al.Randomized Clinical Trial to Compare Micropulse Photocoagulation Versus Half-dose Verteporfin Photodynamic Therapy in the Treatment of Central Serous Chorioretinopathy[J].Ophthalmic Surgery Lasers&Imaging Retina,2015,46(8):837-843.
[35]Lai TYY,Chan WM,Li H,et al.Safety enhanced photodynamic therapy with half dose verteporfin for chronic central serous chorioretinopathy:A short term pilot study[J].Digest of the World Core Medical Journals,2006,90(7):869-874.
[36]Lee PY,Kim KS,Lee WK.Severe choroidal ischemia following photodynamic therapy for pigment epithelial detachment and chronic central serous chorioretinopathy[J].Japanese Journal of Ophthalmology,2009,53(1):52-56.
[37]刘洋,黎蕾,徐格致,等.半剂量光动力疗法治疗慢性中心性浆液性脉络膜视网膜病变二年的疗效评估[J].中华眼科杂志,2016,52(5):328-334.
[38]陆慧琴,王尔茜,陈有信.半剂量维替泊芬光动力疗法治疗慢性中心性浆液性脉络膜视网膜病变疗效观察[J].中华眼底病杂志,2015,31(3):226-229.
[39]廖燕红,陈安颍,刘小天.半剂量维替泊芬光动力疗法治疗纤维蛋白渗出慢性中心性浆液性脉络膜视网膜病变观察[J].中国实用眼科杂志,2017,35(2):163-166.
[40]董道权,董应丽,王志立,等.60%剂量维替泊芬光动力疗法治疗慢性中心性浆液性脉络膜视网膜病变的远期效果及安全性[J].中华实验眼科杂志,2015,33(10):945-948.
[41]陈青山,孙良南,李志,等.PDT联合玻璃体腔注射Bevacizumab治疗慢性中心性浆液性视网膜脉络膜病变观察[J].中国实用眼科杂志,2015,33(8):894-898.
[42]吴艺君,许根贵,莫荔,等.半剂量PDT治疗45岁以上中心性浆液性脉络膜视网膜病变疗效观察[J].国际眼科杂志,2017,17(11):2101-2104.
[43]李鹏程,盛双燕,彭冲,等.半剂量光动力疗法治疗慢性中心性浆液性脉络膜视网膜病变[J].中华眼底病杂志,2011,27(4):327-330.
[44]王玉风.半量维替泊芬光动力疗法对黄斑区脉络膜视网膜病变(中心性浆液性)治疗效果分析[J].北方药学,2017,14(6):43.
[45]Zavoloka O,Bezditko P,Lahorzhevska I,et al.Clinical efficiency of Helicobacter pylori,eradication in the treatment of patients with acute central serous chorioretinopathy[J].Graefes Arch Clin and Exp Ophthalmol,2016,254(9):1737-1742.
[46]Schaal KB,Legarreta AD,Feuer WJ,et al.Comparison between Widefield En Face Swept-Source OCT and Conventional Multimodal Imaging for the Detection of Reticular Pseudodrusen[J].Ophthalmology,2017,124(2):205-214.
[47]Asahi MG,Chon AT,Gallemore E,et al.Photodynamic therapy combined with antivascular endothelial growth factor treatment for recalcitrant chronic central serous chorioretinopathy[J].Clinical Ophthalmology,2017,11(11):2051-2056.
[48]Abouammoh MA.Advances in the treatment of central serous chorioretinopathy.[J].Saudi Journal of Ophthalmology,2015,29(4):278-286.
[49]莫宾,周海英,焦璇,等.中心性浆液性脉络膜视网膜病变的OCTA特点及与ICGA的比较分析[J].国际眼科杂志,2017,17(7):1351-1355.
[50]赵俊华,何剑峰.中心性浆液性脉络膜视网膜病变治疗方法的研究进展[J].中国临床新医学,2017,10(8):816-820.
[51]连海燕,宋艳萍.阈下微脉冲激光光凝对慢性中心性浆液性脉络膜视网膜病变的疗效分析[J].眼科,2017,26(3):185-190.
[52]韦远鹏,杨万初.激光光凝眼底联合卵磷脂络合碘片在中心性浆液性脉络膜视网膜病变治疗中的价值分析[J].临床医药文献电子杂志,2017,4(51):9982-9983.
[53]Golshahi A,Klingmüller D,Holz FG,et al.Ketoconazole in the treatment of central serous chorioretinopathy:a pilot study[J].Acta Ophthalmologica,2010,88(5):576-581.
[54]Artunay O,Yuzbasioglu E,Rasier R,et al.Intravitreal bevacizumab in treatment of idiopathic persistent central serous chorioretinopathy:a prospective,controlled clinical study[J].Current Eye Research,2010,35(2):91-98.
[55]Lee JY,Rohlman CE,Molony LA,et al.Characterization of RPR1,an essential gene encoding the RNA component of Saccharomyces cerevisiae nuclear RNase P[J].Molecular&Cellular Biology,1991,11(2):721-730.
[56]Alejandra D,Alexandre M,Ali D,et al.Oral MineralocorticoidReceptor Antagonists:Real-Life Experience in Clinical Subtypes of Nonresolving Central Serous Chorioretinopathy With Chronic Epitheliopathy[J].Translational Vision Science&Technology,2016,5(2):1-12.
[57]Pryds A,Larsen M.Choroidal thickness following extrafoveal photodynamic treatment with verteporfin in patients with central serous chorioretinopathy[J].Acta Ophthalmologica,2012,90(8):738-743.
[58]Ueng SW,Yuan LJ,Lin SS,et al.Hyperbaric oxygen treatment prevents nitric oxide-induced apoptosis in articular cartilage injury via enhancement of the expression of heat shock protein 70[J].Journal of Orthopaedic Research Official Publication of the Orthopaedic Research Society,2013,31(3):376-384.
[59]Fujita S,Arai Y,Nakagawa S,et al.Combined microwave irradiation and intraarticular glutamine administration-induced HSP70 expression therapy prevents cartilage degradation in a rat osteoarthritis model[J].Journal of Orthopaedic Research Society,2012,30(3):401-407.
[60]Li JS,Zhang W,Kang ZM,et al.Hyperbaric oxygen preconditioning reduces ischemia-reperfusion injury by inhibition of apoptosis via mitochondrial pathway in rat brain[J].Neuroscience,2009,159(4):1309-1315.
[61]Arai Y,Kubo T,Kobayashi K,et al.Adenovirus vectormediated gene transduction to chondrocytes:in vitro evaluation of therapeutic efficacy of transforming growth factor-beta 1 and heat shock protein 70 gene transduction[J].Journal of Rheumatology,1997,24(9):1787-1795.
[62]Weisz G,Lavy A,Adir Y,et al.Modification of in Vivo,and in Vitro,TNF-α,IL-1,and IL-6 Secretion by Circulating Monocytes During Hyperbaric Oxygen Treatment in Patients with Perianal Crohn's Disease[J].Journal of Clinical Immunology,1997,17(2):154-159.
[63]王亚明,付婧.高压氧治疗复发性中浆病23例分析[J].中华医学写作杂志,2003,10(8):723-724.
[64]杨欢.中心性浆液性脉络膜视网膜病变患者的多焦视网膜电图改变以及与视力和黄斑区视网膜下液厚度的相关性[D].南充:川北医学院,2017.
[65]Schl9tzer-Schrehardt U,Viestenz A,Naumann GO,et al.Doserelated structural effects of photodynamic therapy on choroidal and retinal structures of human eyes[J].Graefe's Archive for Clinical&Experimental Ophthalmology,2002,240(9):748-757.